Delta-Fly Pharma Inc.: Patient recruitment begins in the Phase I/II combination study of DFP-10917 with venetoclax in patients with myeloid leukemia (AML)

After the previous information from April 8, 2024 we will be happy to welcome you with new entwicklungs.

The U.S. Food and Drug Administration (FDA) on April 8 conducted a Phase I/II clinical trial of DFP-10917 in combination with Venetoclax (VEN) in patients with myeloid leukemia (AML). Treatment with the VEN therapy is being conducted (Delta-Fly Pharma Inc.: Confirmed Completion of Genetic Support for the Continuation of the Phase I/II Study of DFP-10917 in Combination with Venetoclax | Business Wire). Now we are happy to announce that after confirmation by the Investigational Review Board (IRB) of the first patient to be considered in the study at the University of Virginia Hospital. The University of Virginia Hospital is conducting the clinical trial, in most patients in the Phase III study of monotherapy with DFP-10917 in patients with failed/refused AML treatment.